Analysis of 3 markers of angiogenesis: ANGPT2, VEGF and HB-EGF can become a prognostic panel to assess the course of MM and predict the use of angiogenesis-oriented therapy. The gene discussed is VEGFA; the disease is Miyoshi myopathy.